SCHRES-06226; No of Pages 5 Schizophrenia Research xxx (2015) xxx–xxx

Contents lists available at ScienceDirect

Schizophrenia Research journal homepage: www.elsevier.com/locate/schres

A population-based cohort study on deep vein thrombosis and pulmonary embolism among schizophrenia patients Wen-Yu Hsu a,b,c, Hsien-Yuan Lane a,d, Cheng-Li Lin e,f, Chia-Hung Kao g,h,⁎ a

Graduate Institute of Clinical Medical Science, China Medical University, Taichung, Taiwan Department of Psychiatry, Changhua Christian Hospital, Changhua, Taiwan School of Medicine, Chung Shan Medical University, Taichung, Taiwan d Department of Psychiatry, China Medical University and Hospital, Taichung, Taiwan e Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan f College of Medicine, China Medical University, Taichung, Taiwan g Graduate Institute of Clinical Medical Science and School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan h Department of Nuclear Medicine and PET Center, China Medical University Hospital, Taichung, Taiwan b c

a r t i c l e

i n f o

Article history: Received 13 November 2014 Received in revised form 31 December 2014 Accepted 6 January 2015 Available online xxxx Keywords: Schizophrenia Deep vein thrombosis Pulmonary embolism National Health Insurance Research Database

a b s t r a c t Objective: Several risk factors of venous thromboembolism (VTE) and pulmonary embolism (PE) were found in patients with schizophrenia. Therefore, we hypothesize that the incidences of VTE and PE are relatively higher among schizophrenia patients in comparison with the general population. Method: For this population-based cohort study, claims data from 1996 to 2011 were obtained from the National Health Insurance Research Database in Taiwan. We compared the incidence of DVT and PE between schizophrenia and non-schizophrenia cohorts. Cox proportional hazard regression models were used to analyze the risk of DVT and PE, according to sex, age, and comorbidities. Results: Compared with the non-schizophrenia cohort, the schizophrenia cohort exhibited a 2.02-fold higher adjusted hazard ratio (HR) for developing DVT, and a 1.99-fold higher adjusted HR for developing PE. Furthermore, schizophrenia patients using first-generation or second-generation antipsychotics exhibited a higher adjusted HR for both DVT and PE development. Conclusion: Compared with the general population, the risk of DVT and PE is relatively higher among schizophrenia patients. Early diagnosis and intervention by physicians could mitigate complications and reduce mortality resulting from VTE. © 2015 Elsevier B.V. All rights reserved.

1. Introduction In the United States, the annual incidence of venous thromboembolisms (VTEs), including deep vein thrombosis (DVT) and pulmonary embolism (PE), is approximately 1 per 1000 adults, causing discomfort, suffering, and occasionally death (White, 2003). Death occurs within one month of incidence in approximately 6% of patients with DVT and in 10% of those with PE (Cushman et al., 2004). Several studies have identified age, immobilization, obesity, smoking status, allergy, autoimmune disease, heart failure, lower leg fracture, surgery, diabetes, pregnancy, antipsychotics, physical restraint and cancer as acquired risk factors for VTE. Few studies have investigated DVT and PE in patients with schizophrenia. Schizophrenia is a chronic, severe, and disabling ⁎ Corresponding author at: Graduate Institute of Clinical Medical Science and School of Medicine, College of Medicine, China Medical University, No. 2, Yuh-Der Road, Taichung 404, Taiwan. Tel.: +886 4 22052121x7412; fax: +886 4 22336174. E-mail address: [email protected] (C.-H. Kao).

brain disorder. Worldwide, the lifetime prevalence of schizophrenia is approximately 1%. Schizophrenia patients also have more physical problems than general population. In the recent Canada study, they found that schizophrenia patients are at increased risk of death compared to the general population, and the majority of these deaths are occurring in older age from physical disease processes (Kredentser et al., 2014). As we have known, there are several risk factors of DVT and PE in schizophrenia patients. These factors might increase risk of DVT and PE in this population. Patients with schizophrenia may exhibit long-term positive, negative, cognitive, or affective symptoms. Negative symptoms include blunted or flat affect, alogia, avolition, apathy, anticipatory anhedonia, and asociality (Choi and Medalia, 2010; Foussias and Remington, 2010; Blanchard et al., 2011). Avolition was found to be a significant predictor for motor activity levels in patients with schizophrenia (Docx et al., 2013). Immobilization was associated with risk of DVT and PE in previous study (Beam et al., 2009). And, increased risk of VTE among subjects with current antipsychotic use was found (Wu et al., 2013). Besides, high tobacco smoking rate in schizophrenia might increase risk of

http://dx.doi.org/10.1016/j.schres.2015.01.012 0920-9964/© 2015 Elsevier B.V. All rights reserved.

Please cite this article as: Hsu, W.-Y., et al., A population-based cohort study on deep vein thrombosis and pulmonary embolism among schizophrenia patients, Schizophr. Res. (2015), http://dx.doi.org/10.1016/j.schres.2015.01.012

2

W.-Y. Hsu et al. / Schizophrenia Research xxx (2015) xxx–xxx

DVT and PE (Severinsen et al., 2009; Cooper et al., 2012; Blondon et al., 2013; Minichino et al., 2013). High metabolic syndrome risk in this population also increases the risk of DVT and PE (Kawasaki et al., 1997; Vazzana et al., 2012; Chang et al., 2013; Klovaite et al., 2014). We hypothesize that the incidence of VTE is higher among schizophrenia patients in comparison with the general population. Accordingly, this population-based cohort study was conducted to investigate whether DVT and PE are more prevalent among schizophrenia patients in Taiwan.

Codes 72–74), and lower leg fracture or surgery (ICD-9 Codes 820–823, as well as Procedure Codes 81.51, 81.52, 81.53, and 81.54) as preexisting comorbidities that were potential confounders in the association with DVT and PE. Information on benzodiazepine (BZD) treatment at the baseline was obtained. We hypothesized that first-generation antipsychotics, and second-generation antipsychotics have different effects on DVT and PE in schizophrenia patients.

2. Methods

The study participants were followed from the index date until DVT or PE diagnosis, withdrawal from the insurance program, censoring because of death, or the end date of the database (December 31, 2011).

2.1. Data source This study used data that were obtained from the National Health Insurance Research Database (NHIRD), which contains claims data from 1996 to 2011 related to inpatient care, ambulatory care, dental care, and prescription drugs. In Taiwan, national health care is obligatory, and few people are excluded from the system. The National Health Insurance (NHI) program, which was implemented on March 1, 1995, provides insurance coverage for approximately 99% of Taiwan's population of approximately 23.74 million people (http://www.nhi. gov.tw/english/index.aspx). The NHI catastrophic illness files—the Registry of Catastrophic Illnesses Patient Database (RCIPD)—were established to track patients with major or catastrophic illnesses, including cancer, end-stage renal disease, autoimmune diseases, congenital illness, and several mental illness, such as schizophrenia. To validate the diagnosis of patients, the Bureau of NHI routinely reviews the original medical charts of all patients who apply for catastrophic illness registration. This study analyzed depersonalized secondary data; thus, no informed consent was required. This study was approved by the Ethics Review Board of China Medical University (CMU-REC-101-012). Diagnostic codes are reported based on the International Classification of Disease, 9th Revision, Clinical Modification (ICD-9-CM). 2.2. Participant selection The study subjects were identified from the following two subsets of the NHIRD: First, cases were confirmed from the RCIPD. The schizophrenia cohort comprised patients aged 20 years who were newly diagnosed with schizophrenia (ICD-9-CM Code 295 except 295.8) between 2000 and 2011. The index date was set as the date at which the schizophrenia patients were registered for catastrophic illness; second, the control patient data were obtained from the LHID2000, which is a database containing longitudinally linked claims data (from 1996 to 2011) of one million people randomly sampled from the NHIRD. The National Health Research Institutes reported that the difference in age, sex, and health care costs between the LHID2000 and all enrollees is nonsignificant. A nonschizophrenia comparison cohort was randomly selected from the LHID2000, comprising patients without schizophrenia and frequency matched with the schizophrenia cohort at a 4:1 ratio based on age (in 5-year increments), sex, and year of diagnosis. For both cohorts, patients with a history of DVT (ICD-9-CM 453.8) or PE (ICD-9-CM 415.1, excluding ICD-9-CM 415.11) before the index date, as well as those with incomplete age or sex information were excluded. 2.3. Variables We considered atrial fibrillation (ICD-9 Code 427.31), hypertension (ICD-9 Codes 401–405), diabetes (ICD-9 Code 250), cerebral vascular disease (CVA; ICD-9 Codes 430–438), heart failure (ICD-9 Code 428), all types of cancer (ICD-9 Codes 140–208), pregnancy (ICD-9 Codes 640.× 1–676.× 1, 640.× 2–676.× 2, and 650–659, as well as Procedure

2.4. Main outcome

2.5. Statistical analysis All analyses were performed using SAS for Windows (version 9.3; SAS Institute, Inc., Cary, NC, USA). A two-tailed P value of 0.05 was considered statistically significant. Pearson's chi-square test was used for categorical variables, such as age group (20–34, 35–49, and ≥ 50 years), sex, comorbidities, and BZD treatment between the schizophrenia and nonschizophrenia cohorts. Continuous variables were analyzed using a two-sample t test. The cumulative incidence of DVT or PE among the schizophrenia and nonschizophrenia cohorts was assessed using the Kaplan–Meier method, and the differences were assessed with a log-rank test. The overall, gender-, age-, and comorbidity-specific incidence rates (per 10 000 person-years) were calculated for each cohort. Univariable and multivariable Cox proportional hazard regression analyses were used to assess the risk of DVT and PE development associated with schizophrenia, compared with that of the nonschizophrenia cohort. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated in the Cox models. For the multivariable model, the effects of sex, age, and comorbidities were controlled to determine whether these factors cause any significant difference between the two cohorts (Table 1).

Table 1 Comparison of demographics and comorbidity between schizophrenia patients and controls.

Age, years 20–34 35–49 N50 Mean (SD)† Gender Female Male Comorbidity Atrial fibrillation Hypertension Hyperlipidemia Diabetes CVA Heart failure All cancer Pregnancy Lower leg fracture or Surgery BZD

P-value

Control subjects (N = 60,264) n(%)

Schizophrenia (N = 60,264) n(%)

26,777(44.4) 21,635(35.9) 11,852(19.7) 38.7(13.8)

26,777(44.4) 21,635(35.9) 11,852(19.7) 38.8(13.3)

28,609(47.5) 31,655(52.5)

28,609(47.5) 31,655(52.5)

130(0.22) 7406(12.3) 5615(9.32) 2064(3.42) 602(1.00) 402(0.67) 673(1.12) 5874(9.75) 711(1.18)

107(0.18) 7219(12.0) 4498(7.46) 2737(4.54) 991(1.64) 532(0.88) 440(0.73) 3463(5.75) 1276(2.12)

0.13 0.10 b0.001 b0.001 b0.001 b0.001 b0.001 b0.001 b0.001

31,327(52.0)

55,826(92.6)

b0.001

0.99

0.08 0.99

Chi-square test examined categorical data. CVA denotes cerebral vascular disease. BZD denotes Benzodiazepines. † t-Test examined continuous.

Please cite this article as: Hsu, W.-Y., et al., A population-based cohort study on deep vein thrombosis and pulmonary embolism among schizophrenia patients, Schizophr. Res. (2015), http://dx.doi.org/10.1016/j.schres.2015.01.012

W.-Y. Hsu et al. / Schizophrenia Research xxx (2015) xxx–xxx

3. Results Our study included 60,264 patients with schizophrenia and 60,264 control patients without schizophrenia. Among the schizophrenia patients, 52.5% of them were men and 44.4% of them were younger than 34 years of age (Table 1). The mean ages of the schizophrenia and nonschizophrenia cohorts are 38.8 ± 13.3 years and 38.7 ± 13.8 years, respectively. Compared with the nonschizophrenia cohort, the schizophrenia patients exhibited a higher prevalence of diabetes, CVA, heart failure, lower leg fracture or surgery, and BZD treatment (P b 0.001). Compared with schizophrenia patients, those without schizophrenia typically had a higher prevalence of hyperlipidemia, cancer, and pregnancy (P b 0.001). The Kaplan–Meier analysis results show that the cumulative incidence curves of DVT were significantly higher in the schizophrenia cohort than in the nonschizophrenia cohort (log-rank test P b 0.001; Fig. 1A). During the mean follow-up period of 6.40 years for the schizophrenia cohort and 6.48 years for the non-schizophrenia cohort, the overall incidence density of DVT was significantly higher (2.06-fold) in schizophrenia cohort than in the nonschizophrenia cohort (4.17 vs 2.02 per 10 000 person-years) with an adjusted HR of 2.02 (95% CI = 1.52–2.70) after adjusting the model to control the effects of age, sex, comorbidities, and BZD treatment (Table 2). In both cohorts, the DVT incidence was higher in women than in men. The sex-specific schizophrenia cohort to nonschizophrenia cohort relative risk of DVT development is significantly higher for both women (adjusted HR = 1.65, 95% CI = 1.15–2.36) and men (adjusted HR = 2.94, 95% CI = 1.79–4.83). The age-specific schizophrenia cohort to nonschizophrenia cohort relative risk of DVT development is significantly higher for patients younger 54 years (adjusted HR = 2.64, 95% CI = 1.07–6.53) and those aged 55–69 years (adjusted HR = 2.63, 95% CI = 1.61–4.30). Compared with the nonschizophrenia cohort, the schizophrenia patients exhibited a higher risk of developing DVT for those patients without comorbidities (adjusted HR = 2.10, 95% CI = 1.41–3.15). Fig. 1B shows the cumulative PE incidence curve for the two cohorts, as well as cases where the schizophrenia cohort incidence curve is significantly higher than that of the nonschizophrenia cohort (log-rank test P = 0.002). Overall, the risk of developing PE was 1.99-fold higher among the schizophrenia cohort in comparison with the nonschizophrenia cohort (95% CI = 1.21–3.27) after adjusting the model to control the effects of age, sex, comorbidities, and BZD treatment. The sex-specific analysis results indicate that the risk of PE development is significantly higher among women in the

3

schizophrenia cohort compared with those in the nonschizophrenia cohort (adjusted HR = 1.97; 95% CI = 1.03–3.78). Further analysis was performed to assess whether the antipsychotic medications influenced the DVT and PE outcomes. (Supplementary table). We observed that the schizophrenia patients receiving firstgeneration antipsychotics or receiving second-generation antipsychotic treatment exhibited a higher risk of DVT and PE development than those without schizophrenia. 4. Discussion Our results show that the schizophrenia patients have a 2.02-fold (1.99-fold) higher adjusted HR for DVT (PE) development than the nonschizophrenia cohort. In the United States from 2002 to 2007, Khaykin et al. reported that hospitalizations of patients with secondary diagnosis of schizophrenia were associated with a higher probability of developing PE or DVT compared to the general population (Khaykin et al., 2010). Daumit et al. reported that hospitalizations of schizophrenia patients had a relatively higher adjusted odd for postoperative DVT development in comparison with those without schizophrenia (Daumit et al., 2006). Both of those studies reported higher risks for DVT or PE development among non-psychiatric hospitalizations of schizophrenia patients compared with non-schizophrenia patients. Few studies have investigated the association between schizophrenia and DVT or PE development. This study is the first showing that the risk of DVT and PE development is higher among schizophrenia patients compared with non-schizophrenia patients. Furthermore, the schizophrenia cohort receiving first-generation or second-generation antipsychotics exhibited a higher adjusted HR for DVT and PE development in comparison with the non-schizophrenia cohort. This result is similar to findings of several previous studies (Liperoti et al., 2005; Masopust et al., 2007; Wu et al., 2013). Masopust et al. indicated a potentially increased risk of VTE development in patients using antipsychotic drugs (Masopust et al., 2007). Wu et al. reported that current antipsychotic drug use was associated with a 52% increased risk of developing VTE (Wu et al., 2013). Furthermore, they showed that all classes of antipsychotics were associated with increased risk of VTE. Liperoti et al. reported that second-generation antipsychotics, including risperidone, olanzapine, clozapine, and quetiapine, appear to increase the risk of developing VTE (Liperoti et al., 2005). However, this study observed no increased risk associated with using phenothiazine or other first-generation antipsychotic agents. Many patients with schizophrenia would have had different antipsychotic during

Fig. 1. Cumulative incidence of deep vein thrombosis (DVT) (A) and pulmonary embolism (PE) (B) in patients with schizophrenia and comparison patients.

Please cite this article as: Hsu, W.-Y., et al., A population-based cohort study on deep vein thrombosis and pulmonary embolism among schizophrenia patients, Schizophr. Res. (2015), http://dx.doi.org/10.1016/j.schres.2015.01.012

4

W.-Y. Hsu et al. / Schizophrenia Research xxx (2015) xxx–xxx

Table 2 Incidence and adjusted hazard ratio of DVT and PE by sex, age and comorbidity for schizophrenia patients compared to controls. Control subjects Variables DVT All Gender Female Male Age, years ≤54 55–69 N70 Comorbidity§ No Yes PE All Gender Female Male Age, years ≤54 55–69 N70 Comorbidity§ No Yes

Schizophrenia

Compared to control

Events n

PY

Rate#

Events n

PY

Rate#

Crude HR* (95% CI)

Adjusted HR† (95% CI)

79

390,586

2.02

161

385,637

4.17

2.06(1.58, 2.70)⁎⁎⁎

2.02(1.52, 2.70)⁎⁎⁎

52 27

182,854 207,732

2.84 1.30

85 76

180,658 204,979

4.71 3.71

1.66(1.17, 2.34)⁎⁎ 2.85(1.84, 4.42)⁎⁎⁎

1.65(1.15, 2.36)⁎⁎⁎ 2.94(1.79, 4.83)⁎⁎⁎

9 25 45

176,440 142,310 71,836

0.51 1.76 6.26

30 72 59

178,539 140,129 66,969

1.68 5.14 8.81

3.30(1.56, 6.94)⁎⁎ 2.93(1.86, 4.61)⁎⁎⁎ 1.42(0.96, 2.09)

2.64(1.07, 6.53)⁎ 2.63(1.61, 4.30)⁎⁎⁎ 1.42(0.95, 2.12)

38 41

289,435 101,151

1.31 4.05

98 63

300,867 84,770

3.26 7.43

2.48(1.70, 3.61)⁎⁎⁎ 1.84(1.24, 2.73)⁎⁎

2.10(1.41, 3.15)⁎⁎⁎ 1.75(1.16, 2.63)⁎⁎⁎

27

390,769

0.69

55

385,961

1.43

2.06(1.30, 3.27)⁎⁎

1.99(1.21, 3.27)⁎⁎

15 12

182,982 207,787

0.82 0.58

29 26

180,811 205,150

1.60 1.27

1.96(1.05, 3.65)⁎ 2.20(1.11, 4.36)⁎

1.97(1.03, 3.78)⁎ 2.06(0.94, 4.49)

5 7 15

176,440 142,379 71,950

0.28 0.49 2.08

14 16 25

178,633 140,293 67,035

0.78 1.14 3.73

2.78(1.00, 7.71)⁎ 2.31(0.95, 5.62) 1.80(0.95, 3.42)

2.11(0.62, 7.20) 2.05(0.77, 5.48) 1.84(0.95, 3.57)

16 11

289,502 101,268

0.55 1.09

35 20

301,066 84,895

1.16 2.36

2.10(1.16, 3.80)⁎ 2.17(1.04, 4.54)⁎

1.84(0.96, 3.53) 2.08(0.98, 4.40)

PY, person-years; rate#, incidence rate, per 10,000 person-years; crude HR*: relative hazard ratio; adjusted HR†: adjusted hazard ratio controlling for age, sex, and comorbidities of atrial fibrillation, hypertension, diabetes, CVA, heart failure, all cancer, pregnancy and lower leg fracture or surgery and medication of BZD; comorbidity§: patients with any one of the comorbidities atrial fibrillation, hypertension, diabetes, CVA, heart failure, all cancer, pregnancy and lower leg fracture or surgery were classified as the comorbidity group. ⁎ P b 0.05. ⁎⁎ P b 0.01. ⁎⁎⁎ P b 0.001.

their life-time, and there is no correction for duration of potential exposure in this study. But, antipsychotics play a critical role in DVT and PE development in schizophrenia patients. Based on the findings of this study, antipsychotics should be considered a contributing factor of DVT and PE development. In this study, the schizophrenia cohort exhibited a higher incidence of DVT and PE compared with the non-schizophrenia cohort, which could be related to several factors. First, the negative symptoms of schizophrenia could lead to a decrease in activities of daily living among schizophrenia; moreover, antipsychotics could also lead to a reduction in daily activity. Hypoactivity and immobility increase the risk of developing DVT and PE (Beam et al., 2009). Second, antipsychotic exposure could increase the risk of DVT and PE (Wu et al., 2013; Barbui et al., 2014). Third, schizophrenia patients who are physically restrained could be at greater risk of DVT and PE development (De Hert et al., 2010; Cecchi et al., 2012). Fourth, higher rates of smoking and metabolic syndrome among schizophrenia patients could also increase the risk (Kawasaki et al., 1997; de Leon and Diaz, 2005; Severinsen et al., 2009; Vazzana et al., 2012; Blondon et al., 2013; Chang et al., 2013; Klovaite et al., 2014). The strength of our findings is the result of the nationwide population-based design of this longitudinal study on the risks of DVT and PE development among in schizophrenia patients in Taiwan. In addition, the diagnosis of all of schizophrenia patients identified in the NHIRD claims data was confirmed through their inclusion in the RCIPD, indicating that the data are highly reliable. Because all residents in Taiwan are assigned a unique personal identification number, the medical history of all patients could be traced throughout the entire follow-up period. Thus, our findings are generalizable to the entire population of Taiwan. However, some limitations were encountered while conducting this study. First, the accuracy of DVT and PE incidence was not validated by reviewing medical charts, and VTE cases were identified based only on ICD-9-CM Codes 415.1 (PE) and 453.8 (DVT). Second,

in our analysis, a lack of data (e.g., smoking status, obesity, physical restraint, hormone replacement therapy, the use of contraceptive drugs, and glucocorticosteroid treatment) may have influenced the results of this study. Therefore, we used proxy measures (e.g., such as hyperlipidemia and diabetes as indicators of obesity) to control the potential effects of unmeasurable confounders. However, some unmeasured confounders could not be addressed by this study. Third, our comparison cohort included inpatients, which may have reduced the potential for overestimating the risk, specifically because VTE is a typical complication during and after hospitalization for acute medical illness or surgery. In conclusion, this nationwide population-based cohort study shows that schizophrenia patients have a 2.02-fold (1.99-fold) higher adjusted HR for DVT (PE) development in comparison with the non-schizophrenia cohort. These findings indicate the importance of using a multidisciplinary approach in managing the potential risk factors for DVT and PE development among schizophrenia patients, particularly those who, because of their illness, are unable to maintain adequate personal care or gain access to health care by themselves. Occasionally, DVT is a “silent” disease; for patients with schizophrenia, identifying the early signs of DVT may be difficult. In this study, higher incidences of DVT and PE were observed in the schizophrenia cohort than in non-schizophrenia cohort. Regular physical examinations and history taking are critical to detect DVT and PE. Early diagnosis and intervention could mitigate complications or and reduce mortality. Supplementary data to this article can be found online at http://dx. doi.org/10.1016/j.schres.2015.01.012. Contributors All authors have contributed substantially to, and are in agreement with the content of, the manuscript: Conception/design: Wen-Yu Hsu, Chia-Hung Kao; provision of study materials: Chia-Hung Kao; collection and/or assembly of data: all authors; data analysis and interpretation: all authors; manuscript preparation: all authors; final approval of manuscript: all authors. The guarantor of the paper, taking responsibility for the integrity of the work as a whole, from inception to published article: Chia-Hung Kao.

Please cite this article as: Hsu, W.-Y., et al., A population-based cohort study on deep vein thrombosis and pulmonary embolism among schizophrenia patients, Schizophr. Res. (2015), http://dx.doi.org/10.1016/j.schres.2015.01.012

W.-Y. Hsu et al. / Schizophrenia Research xxx (2015) xxx–xxx Conflict of interest All authors state that they have no conflicts of interest.

Acknowledgments This work was supported by study grants (DMR-103–012) from the China Medical University Hospital, Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence (MOHW103-TDU-B-212-113002), Health, and welfare surcharge of tobacco products, China Medical University Hospital Cancer Research Center of Excellence (MOHW104-TD-B-111-03, Taiwan). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding received for this study.

References Barbui, C., Conti, V., Cipriani, A., 2014. Antipsychotic drug exposure and risk of venous thromboembolism: a systematic review and meta-analysis of observational studies. Drug Saf. 37 (2), 79–90. Beam, D.M., Courtney, D.M., Kabrhel, C., Moore, C.L., Richman, P.B., Kline, J.A., 2009. Risk of thromboembolism varies, depending on category of immobility in outpatients. Ann. Emerg. Med. 54 (2), 147–152. Blanchard, J.J., Kring, A.M., Horan, W.P., Gur, R., 2011. Toward the next generation of negative symptom assessments: the collaboration to advance negative symptom assessment in schizophrenia. Schizophr. Bull. 37 (2), 291–299. Blondon, M., Wiggins, K.L., McKnight, B., Psaty, B.M., Rice, K.M., Heckbert, S.R., 2013. The association of smoking with venous thrombosis in women. A population-based, case-control study. Thromb. Haemost. 109 (5), 891–896. Cecchi, R., Lazzaro, A., Catanese, M., Mandarelli, G., Ferracuti, S., 2012. Fatal thromboembolism following physical restraint in a patient with schizophrenia. Int. J. Legal Med. 126 (3), 477–482. Chang, J.C., Yen, A.M., Lee, C.S., Chen, S.L., Chiu, S.Y., Fann, J.C., 2013. A population-based cohort study to elucidate temporal relationship between schizophrenia and metabolic syndrome (KCIS no. PSY3). Schizophr. Res. 151 (1–3), 158–164. Choi, J., Medalia, A., 2010. Intrinsic motivation and learning in a schizophrenia spectrum sample. Schizophr. Res. 118 (1–3), 12–19. Cooper, J., Mancuso, S.G., Borland, R., Slade, T., Galletly, C., Castle, D., 2012. Tobacco smoking among people living with a psychotic illness: the second Australian survey of psychosis. Aust. N. Z. J. Psychiatr. 46 (9), 851–863. Cushman, M., Tsai, A.W., White, R.H., Heckbert, S.R., Rosamond, W.D., Enright, P., 2004. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am. J. Med. 117 (1), 19–25.

5

Daumit, G.L., Pronovost, P.J., Anthony, C.B., Guallar, E., Steinwachs, D.M., Ford, D.E., 2006. Adverse events during medical and surgical hospitalizations for persons with schizophrenia. Arch. Gen. Psychiatry 63 (3), 267–272. De Hert, M., Einfinger, G., Scherpenberg, E., Wampers, M., Peuskens, J., 2010. The prevention of deep venous thrombosis in physically restrained patients with schizophrenia. Int. J. Clin. Pract. 64 (8), 1109–1115. de Leon, J., Diaz, F.J., 2005. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr. Res. 76 (2–3), 135–157. Docx, L., Sabbe, B., Provinciael, P., Merckx, N., Morrens, M., 2013. Quantitative psychomotor dysfunction in schizophrenia: a loss of drive, impaired movement execution or both? Neuropsychobiology 68 (4), 221–227. Foussias, G., Remington, G., 2010. Negative symptoms in schizophrenia: avolition and Occam's razor. Schizophr. Bull. 36 (2), 359–369. Kawasaki, T., Kambayashi, J., Ariyoshi, H., Sakon, M., Suehisa, E., Monden, M., 1997. Hypercholesterolemia as a risk factor for deep-vein thrombosis. Thromb. Res. 88 (1), 67–73. Khaykin, E., Ford, D.E., Pronovost, P.J., Dixon, L., Daumit, G.L., 2010. National estimates of adverse events during nonpsychiatric hospitalizations for persons with schizophrenia. Gen. Hosp. Psychiatry 32 (4), 419–425. Klovaite, J., Benn, M., Nordestgaard, B.G., 2014. Obesity as a causal risk factor for deep venous thrombosis: a Mendelian randomization study. J. Intern. Med. Kredentser, M.S., Martens, P.J., Chochinov, H.M., Prior, H.J., 2014. Cause and rate of death in people with schizophrenia across the lifespan: a population-based study in Manitoba, Canada. J. Clin. Psychiatry 75 (2), 154–161. Liperoti, R., Pedone, C., Lapane, K.L., Mor, V., Bernabei, R., Gambassi, G., 2005. Venous thromboembolism among elderly patients treated with atypical and conventional antipsychotic agents. Arch. Intern. Med. 165 (22), 2677–2682. Masopust, J., Maly, R., Urban, A., Hosak, L., Cermakova, E., 2007. Antipsychotic drugs as a risk factor for venous thromboembolism. Int. J. Psychiatry Clin. Pract. 11 (3), 246–249. Minichino, A., Bersani, F.S., Calo, W.K., Spagnoli, F., Francesconi, M., Vicinanza, R., 2013. Smoking behaviour and mental health disorders—mutual influences and implications for therapy. Int. J. Environ. Res. Public Health 10 (10), 4790–4811. Severinsen, M.T., Kristensen, S.R., Johnsen, S.P., Dethlefsen, C., Tjonneland, A., Overvad, K., 2009. Smoking and venous thromboembolism: a Danish follow-up study. J. Thromb. Haemost. 7 (8), 1297–1303. Vazzana, N., Ranalli, P., Cuccurullo, C., Davi, G., 2012. Diabetes mellitus and thrombosis. Thromb. Res. 129 (3), 371–377. White, R.H., 2003. The epidemiology of venous thromboembolism. Circulation 107 (23 Suppl 1), I4–I8. Wu, C.S., Lin, C.C., Chang, C.M., Wu, K.Y., Liang, H.Y., Huang, Y.W., 2013. Antipsychotic treatment and the occurrence of venous thromboembolism: a 10-year nationwide registry study. J. Clin. Psychiatry 74 (9), 918–924.

Please cite this article as: Hsu, W.-Y., et al., A population-based cohort study on deep vein thrombosis and pulmonary embolism among schizophrenia patients, Schizophr. Res. (2015), http://dx.doi.org/10.1016/j.schres.2015.01.012

A population-based cohort study on deep vein thrombosis and pulmonary embolism among schizophrenia patients.

Several risk factors of venous thromboembolism (VTE) and pulmonary embolism (PE) were found in patients with schizophrenia. Therefore, we hypothesize ...
381KB Sizes 0 Downloads 10 Views